Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deulorlatinib vs Crizotinib in Advanced ALK+ NSCLC
NCT06082635Phase 3Active, not recruiting
- Sponsor
- Shenzhen TargetRx
- Start
- Dec 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of deulorlatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shenzhen TargetRx. Primary endpoint: Progression-Free Survival by Independent Review Committee at 1.5 years. Started Dec 2023; status: active, not recruiting.
02
Drugs
deulorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06082635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082635.